{"id":6221,"date":"2019-12-08T12:24:10","date_gmt":"2019-12-08T11:24:10","guid":{"rendered":"http:\/\/wordpress.p545550.webspaceconfig.de\/uncategorized\/dr-simon-moroney-verlaesst-nach-27-jahren-die-morphosys-ag\/"},"modified":"2020-06-11T11:24:05","modified_gmt":"2020-06-11T09:24:05","slug":"dr-simon-moroney-verlaesst-nach-27-jahren-die-morphosys-ag","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/dr-simon-moroney-verlaesst-nach-27-jahren-die-morphosys-ag\/","title":{"rendered":"Dr. Simon Moroney leaves the MorphoSys AG after 27 years"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

Dr. Simon Moroney leaves the MorphoSys AG after 27 years<\/span><\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine-lead”]In February 2020, t\u00adhe biotech expert joins the Novartis Supervisory Board
\n[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]December 2019[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner][vc_column_text]A life science pioneer, Simon Moroney, CEO and co-founder of MorphoSys AG, left the company this summer. Moroney was the head of the biotech company, initially based in Martinsried, for 27 years. Under Moroney’s leadership, MorphoSys developed into one of the key players in the biopharmaceutical industry, with a broad pipeline of drug candidates. Research focuses on medicines for the most severe diseases, such as various forms of cancer. Building on his leading expertise in antibody, protein and peptide technologies, MorphoSys and its partners have built up a pipeline based on more than 100 R&D programs, of which 29 are currently in clinical development. Moroney’s successor is Dr. Jean Paul Kress.[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote”][vc_column_inner][vc_single_image image=”6219″ img_size=”155×155″ alignment=”center” style=”vc_box_circle_2″][vc_column_text el_class=”gco-magazine–picture-discription-blank”]Simon Moroney<\/strong>, former CEO, MorphoSys; today: board member, Novarits[\/vc_column_text][vc_column_text el_class=”gco-magazine-copyright-blank”]<\/p>\n

\u00a9 MorphoSys<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner][vc_column_text]Based in Basel, the pharmaceutical company Novartis has now announced that Moroney will be accepted onto the top board of directors of the pharmaceutical giant at its annual general meeting on February 28, 2020. According to a press release, the company is pleased that “Moroney’s sound scientific knowledge and extensive experience in leading a biotech company” will benefit Novartis in the future.
\n[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n \n
\n MorphoSys AG <\/div>\n\n